RGEN Repligen Corporation

68.94
+1.68  (+3%)
Previous Close 67.26
Open 67.72
Price To Book 5.21
Market Cap 3255716939
Shares 47,225,369
Volume 334,091
Short Ratio
Av. Daily Volume 390,568

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL received June 22, 2012.
RG1068
Detection of pancreatic duct abnormalities

Latest News

  1. Mallinckrodt Ends Enrollment in Phase III for Terlipressin
  2. Edited Transcript of RGEN earnings conference call or presentation 9-May-19 12:30pm GMT
  3. Repligen (RGEN) Q1 2019 Earnings Call Transcript
  4. Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
  5. Repligen: 1Q Earnings Snapshot
  6. Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
  7. Repligen Corp. to Host Earnings Call
  8. Is Repligen's (NASDAQ:RGEN) Share Price Gain Of 273% Well Earned?
  9. Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
  10. See what the IHS Markit Score report has to say about Repligen Corp.
  11. Turtle Beach (HEAR) to Report Q1 Earnings: What's in Store?
  12. Repligen to Report First Quarter 2019 Financial Results
  13. Repligen Corporation Prices Public Offering of Shares of Common Stock
  14. Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
  15. Here’s What Hedge Funds Think About Repligen Corporation (RGEN)
  16. Why Sony, Repligen, and Capital One Financial Jumped Today
  17. Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results
  18. Repligen CEO got 356 percent pay bump for 2018
  19. Before You Buy Repligen Corporation (NASDAQ:RGEN), Consider Its Volatility